Screener
Corcept Therapeutics CORT EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Corcept Therapeutics’s reported figures.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026. Open the filing →
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
FAQ
- What is Corcept Therapeutics's EBITDA?
- Corcept Therapeutics (CORT) reported EBITDA of $42.16M in Q2 2026.
- How has Corcept Therapeutics's EBITDA changed year-over-year?
- Corcept Therapeutics's EBITDA increased by 56.4% year-over-year, from $26.96M to $42.16M.
- What is the long-term trend for Corcept Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Corcept Therapeutics's EBITDA has grown at a -22.2% compound annual growth rate (CAGR), from $125.55M to $45.95M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Corcept Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude